AmyPore

AmyPore is a French biotechnology company dedicated to developing innovative therapies for neurodegenerative disorders, including Alzheimer's and Parkinson's diseases. The company's proprietary technology focuses on preventing the formation of toxic pores in neuronal membranes caused by the aggregation of amyloid-beta and alpha-synuclein proteins. By utilizing therapeutic peptides that target specific ganglioside-binding sites, AmyPore aims to neutralize these toxic oligomers before they cause irreversible cellular damage. Their approach represents a novel strategy in the field of proteopathy, moving beyond simple plaque clearance to functional neuroprotection.